Citius Pharmaceuticals (CTXR) News Today → get a piece of the profit from this land (From True Market Insiders) (Ad) Free CTXR Stock Alerts $0.65 -0.02 (-2.99%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 6:36 PM | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Citius Pharmaceuticals (CTXR)May 14, 2024 | investorplace.comCTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024May 14, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | prnewswire.comCitius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor ConferencesMay 9, 2024 | marketbeat.comCitius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 3.1%Citius Pharmaceuticals (NASDAQ:CTXR) Trading Down 3.1%April 30, 2024 | prnewswire.comCitius Pharmaceuticals Announces Closing of $15 Million Registered Direct OfferingApril 26, 2024 | prnewswire.comCitius Pharmaceuticals Announces $15 Million Registered Direct OfferingApril 14, 2024 | seekingalpha.comCTXR Citius Pharmaceuticals, Inc.April 11, 2024 | prnewswire.comCitius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell LymphomaApril 9, 2024 | marketbeat.comCitius Pharmaceuticals (NASDAQ:CTXR) Trading Down 3.8%Citius Pharmaceuticals (NASDAQ:CTXR) Shares Down 3.8%April 4, 2024 | prnewswire.comCitius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor ConferenceMarch 20, 2024 | finance.yahoo.comCTXR Apr 2024 7.500 putMarch 20, 2024 | finance.yahoo.comCTXR May 2024 2.500 callMarch 20, 2024 | edition.cnn.comCitius Pharmaceuticals IncMarch 18, 2024 | msn.comCitius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatmentMarch 18, 2024 | markets.businessinsider.comCitius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick FactsMarch 18, 2024 | finance.yahoo.comCitius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaMarch 7, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development ProgramMarch 7, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development ProgramFebruary 26, 2024 | finance.yahoo.comCitius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf RegistrationFebruary 26, 2024 | prnewswire.comCitius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf RegistrationFebruary 23, 2024 | finance.yahoo.comCitius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor ConferencesFebruary 14, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business UpdateFebruary 14, 2024 | markets.businessinsider.comBuy Rating for Citius Pharmaceuticals Backed by Resubmission of Lymphir BLA and Potential Orphan Drug ExclusivityFebruary 14, 2024 | finance.yahoo.comCitius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaFebruary 14, 2024 | prnewswire.comCitius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaJanuary 23, 2024 | finance.yahoo.comCitius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of DirectorsJanuary 18, 2024 | marketbeat.comFY2024 Earnings Estimate for Citius Pharmaceuticals, Inc. Issued By HC Wainwright (NASDAQ:CTXR)Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Free Report) - Equities researchers at HC Wainwright issued their FY2024 EPS estimates for shares of Citius Pharmaceuticals in a research note issued on Tuesday, January 16th. HC Wainwright analyst V. Bernardino forecasts that the company will earn ($0.January 15, 2024 | marketbeat.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest UpdateCitius Pharmaceuticals, Inc. (NASDAQ:CTXR - Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 14,620,000 shares, a growth of 8.6% from the December 15th total of 13,460,000 shares. Based on an average daily trading volume, of 557,500 shares, the short-interest ratio is presently 26.2 days.January 4, 2024 | markets.businessinsider.comStrong Buy Rating for Citius Pharmaceuticals Amid Promising Mino-Lok Progress and Strategic Oncology SpinoutJanuary 2, 2024 | finanznachrichten.deCitius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage CathetersJanuary 2, 2024 | baystreet.caCitius Ekes out Gains as Trials EndJanuary 2, 2024 | finance.yahoo.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business UpdateJanuary 2, 2024 | finance.yahoo.comCitius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage CathetersDecember 19, 2023 | marketbeat.comCitius Pharmaceuticals (CTXR) Scheduled to Post Earnings on WednesdayCitius Pharmaceuticals (NASDAQ:CTXR) will be releasing earnings on Wednesday, December 20, Yahoo Finance reports.December 3, 2023 | finance.yahoo.comWe Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth CarefullyNovember 9, 2023 | finance.yahoo.comCitius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023November 8, 2023 | morningstar.comCitius Pharmaceuticals Inc CTXROctober 31, 2023 | finance.yahoo.comCitius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint InhibitorOctober 26, 2023 | markets.businessinsider.comTenX To Acquire Citius Pharma's Oncology Subsidiary Via Merger - Quick FactsOctober 24, 2023 | finance.yahoo.comCitius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.September 18, 2023 | finance.yahoo.comCitius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023September 13, 2023 | finance.yahoo.comCitius Pharmaceuticals Mourns the Loss of Board Member, Howard SafirSeptember 8, 2023 | finance.yahoo.comCitius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™September 6, 2023 | finance.yahoo.comCitius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023September 4, 2023 | finance.yahoo.comBreakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)August 14, 2023 | finance.yahoo.comCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business UpdateAugust 10, 2023 | finance.yahoo.comCitius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 TrialAugust 2, 2023 | msn.comHC Wainwright & Co. Maintains Citius Pharmaceuticals (CTXR) Buy RecommendationAugust 1, 2023 | markets.businessinsider.comCitius Pharmaceuticals (CTXR) Gets a Buy from H.C. Wainwright Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (Ad)Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it. Click on Adam's shiny forehead for more details. CTXR Media Mentions By Week CTXR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTXR News Sentiment▼0.680.42▲Average Medical News Sentiment CTXR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTXR Articles This Week▼41▲CTXR Articles Average Week Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALLK News Today CUE News Today PMVP News Today ASRT News Today GNLX News Today RLMD News Today RZLT News Today SCTL News Today IOBT News Today OPTN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTXR) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
